Posts Tagged ‘Abnormal Blood Cells’



While all the causes of leukemia are still not known, there are risks that have been linked to the development of various types of leukemia. There have been both environmental as well as genetic factors that have shown up as links to leukemia.

The type of leukemia a person has usually depends on the type of abnormal white blood cells that are being produced in the body. Leukemia produces abnormal or immature white blood cells in the bone marrow. At an early development of white blood cells, a blast is the immature form of white blood cells. This is the stage between the stem cell in the bone marrow and the mature blood. Blasts (immature blood cells) are found in limited numbers in the bone marrow of healthy people and not at all in the blood stream. People with leukemia may have high numbers of blasts in the bone marrow and even circulating throughout the circulatory system.

The different types of leukemia are grouped as acute or chronic. An acute leukemia usually produces immature white blood cells that are non-functioning. These cells rapidly reproduce and crowd out the healthy cells. A chronic leukemia produces abnormal blood cells that don’t function as well as normal blood cells. These forms of leukemia are slower acting on the body than the acute forms of leukemia.

Acute myelogenous leukemia (AML) is most common in adults and causes the rapid development of immature white blood cells in the bone marrow crowding out normal cells and spreading these no-functioning cells throughout the body. This interferes in usual work of the normal blood cells. Chronic myelogenous leukemia (CML) causes an increased unregulated growth of myeloid cells in the bone marrow and an elevated amount of white blood cells in the blood. Severe anemia is a result of this overabundance of white cells.

Acute lymphocytic leukemia (ALL) is most common among children under the age of fifteen. In this leukemia the rapid multiplying of malignant immature white blood cells crowds out normal white cells. This type of leukemia responds well to treatment if it is diagnosed in time. In chronic lymphocytic leukemia (CLL) a defective white blood cell is produced in overabundance. This cell does not fight infection and crowds out the healthy cells. Often the chronic lymphocytic leukemia is only discovered after a blood test when the elevated white blood cell count is found.

Some of the risk factors that researchers have identified include high doses of radiation, long-term chemical exposure in the work place, cigarette smoking, and agricultural chemicals. High doses of radiation such as around the failed nuclear reactor at Chernobyl or military exposure during the nuclear detonations in the 1950′s show a strong link to leukemia. Exposure to benzene, herbicides and pesticides have been linked to acute leukemia.

Chronic lymphocytic leukemia has been linked to exposure to agricultural chemicals as has exposure to Agent Orange. Cigarette smoking seems to have an important link to acute leukemia. This is probably due to the chemicals such as benzene, polonium-210 and polycyclic aromatic hydrocarbons. Certain chemotherapy drugs especially alkylating agents combined with ionizing radiation may produce leukemia. Some diseases caused by abnormal chromosomes may increase the risk of leukemia. Philadelphia chromosome is a specific chromosomal abnormality in which parts of two chromosomes swap places. This can lead to acute myelogenous leukemia.

Incoming search terms for the article:

elevated white blood cell count,ABNORMAL WHITE BLOOD CELLS,What causes high white blood cells?,high white blood cell count leukemia,causes of high white blood cell count,causes of elevated white blood cell count,causes for high white blood cell count remedies,Causes Elevated White Blood Count,anemia and high white blood cells,Agent Orange/Benzene/Acute Mylogenous Leukemia,what is a normal white blood cell count



Considered to be a benign disease for years, Myelodysplastic Syndrome (MDS) is nowadays known to pose a serious threat to people it affects. Recent studies have revealed that MDS is actually a malignant disease that can further lead to leukemia. Due to this fact, Myelodysplastic Syndrome is also referred to as pre-leukemia disease.

Similar to leukemia, MDS triggers an overproduction of abnormal blood cells that eventually outnumber their healthy counterparts. The cells involved in causing the disease are called blasts and they originate in the bone marrow. Dysfunctional blasts multiply at abnormally fast rates and accumulate in the marrow or in the bloodstream. These functionless cells perturb the production of normal blood cells, causing a decrease in the number of red blood cells, white blood cells and platelets. As a result, people who suffer from MDS also have anemia, (due to fewer red blood cells), impaired immune system (due to fewer white blood cells) and experience slow healing (due to fewer platelets).

Many patients diagnosed with MDS are at risk of developing leukemia. In order to block the progression of MDS and to prevent the occurrence of leukemia, most patients receive treatments with decitabine, a new drug that is currently under testing.

Although most patients diagnosed with MDS respond well to treatments with mild chemotherapy drugs and decitabine, they commonly experience relapse after completing the prescribed course of medications. MDS has a pronounced recurrent character and despite its high curability in the initial stages of the disease, it becomes very difficult to treat in later stages of evolution.

Oncologists have noticed the fact that patients who relapse also become less responsive to second treatments. The exact reasons why most patients with MDS fail to respond to re-treatment are still unknown. However, this problem may be corrected by extending the duration of initial treatments. Medical scientists explain that a single long-term course of chemotherapy drugs and decitabine may provide better results than frequently repeated shorter treatments. They sustain that by extending the treatment with mild chemotherapy drugs and decitabine beyond the margin of remission, patients with MDS are less likely to relapse. In addition, medical scientists claim that patients who achieve remission should follow ongoing maintenance treatments in order to prevent the recurrence of the disease.

Recently conducted experiments have confirmed the fact that long-term treatments provide better results than repeated treatments in overcoming MDS. Patients who receive short-term treatments not only experience relapse, but they are also more exposed to developing acute leukemia and other severe forms of blood cancer. In order to prevent this from happening, an extended low-dose initial treatment with decitabine followed by maintenance treatments may be the best option for patients diagnosed with MDS.